Protocol Design in Real-World Evidence
The Indispensable Link Between Strategic Need and Study Execution

Marielle Bassel, BA
Research Scientist, Real-World Evidence, Evidera

Laura Sayegh, MScA
Research Associate, Real-World Evidence, Evidera

Sofia Fernandes, MSc
Associate Director, Project Management, Real-World Evidence Evidera

Delphine Saragoussi, MD, MScPH
Senior Research Scientist, Real-World Evidence, Evidera

Introduction
The development of new medical treatments follows a well-known pathway from the assessment of safety to the evaluation of therapeutic efficacy, proceeding to pivotal trials to support market authorization decisions.¹ Pivotal trials are most commonly designed as traditional randomized clinical trials, designed to maximize the chance of demonstrating safety and efficacy and often include restrictive inclusion and exclusion criteria. While such trials are well suited for that purpose, they can leave evidence gaps, including:

• How the therapy is most impactfully incorporated into clinical practice where there may be other available treatment options

• Real-world safety and effectiveness in the broader patient groups that may receive the treatment upon authorization but for whom limited information is available from the pivotal studies

As a result, regulatory approval of a new treatment is often followed by post-marketing evaluations aimed at addressing a variety of questions, including understanding the real-world setting of care, disease, safety, efficacy, or effectiveness of therapy.¹ While there are a number of guidelines and articles that focus on details of the key...
content of a classic clinical trial protocol, few consider the nuances for protocol design when assessing pre- and post-marketing value in the real-world setting.

Non-interventional studies, used to generate real-world evidence (RWE), complement and provide additional insight to the data produced through clinical trials. Pre-approval designs delineate the natural history and course of disease, standard of care, and contribute to the characterization of burden of illness and unmet needs. Post-approval studies are critical for assessing utilization, treatment patterns, comparative effectiveness and safety, and providing overall value demonstration, as well as informing on important therapeutic findings to help guide treatment decisions and real-world use (See Figure 1).

The creation of a study protocol is pivotal in determining the success of the research effort as it is the fundamental document that drives the study, providing pre-defined, standardized procedural methods to effectively communicate plans for study conduct and implementation to all stakeholders and involved parties. Real-world evidence studies differ from clinical trials in nature as they are devoid of any form of intervention. As patient data are gathered and collected during routine clinical care, specific considerations have to be accounted for when developing non-interventional study protocols.

A good protocol should delineate the research questions and outline the research process, show how the design will help achieve the objectives, demonstrate how the study will be operationalized in practice, highlight its feasibility, and convincingly show the importance of the research.

**Stakeholder Involvement in Protocol Development**

Similar to clinical trials, an invaluable aspect of non-interventional protocol development is the engagement of the sponsor to identify and involve key stakeholders and critical reviewers. Internal stakeholders ensure the full consistency of the study within the company’s strategy (See Figure 2). External stakeholders might be end users or approvers of the protocol (See Figure 3). Study type, design, and methods need to be adapted to the research questions and objectives but also to the end users and expected applications of the study results. Factors such as

---

**Figure 1. Objectives of Real-World Evidence across Therapeutic Product Development and Lifecycle**

HTA = health technology assessment; MA = market access; PR = pricing and reimbursement; QoL = quality of life; RMP = risk management plan
study type, design, scope, and research questions may also influence the panel of stakeholders and reviewers based on the study needs and research goals. If, for example, a study includes a rare disease population or an orphan drug, there are benefits in engaging patient community and advocacy groups to gain perspective on the feasibility of the objectives and retention strategies.\(^2\) In addition, the conduct of real-world evidence studies requires review by the ethics committees and may be mandated to support regulatory decisions.\(^3\)

**Features of an RWE Protocol**

Although a real-world study protocol addresses the same principal elements as a clinical trial protocol, there are fundamental differences based on the nature and design of non-interventional studies.\(^2\) The content of these protocols can vary widely according to study objectives and design requirements, nevertheless, there is common content to all non-interventional research protocols, which is presented in Table 1.\(^4\)\(^-\)\(^9\)

**Key Considerations and Challenges of an RWE Protocol**

Understanding the underlying rationale behind the sponsor’s needs to conduct the study drives the direction and elements of the protocol development (See Figure 4). To ensure successful design and implementation of the study, there are key factors and challenges to consider. Protocols written by trained individuals with appropriate scientific background, as well as knowledge on safety, product strategy, and market access will help to mitigate and address these issues.

> “The foundation of a successful study is a protocol that is both scientifically sound and operationally viable.”\(^1\)\(^2\)

- With the involvement of diverse stakeholders and multiple interests, it is crucial to incorporate feedback, while prioritizing input and maintaining focus on the goal of the study.

- In traditional fixed-design clinical trials, treatment protocols are highly controlled and mandate study visits and adherence to protocol-defined procedures at fixed timepoints.\(^3\) Although this approach ensures satisfactory study conduct in a clinical setting, the same might not be permissible in prospective real-world study protocols, especially in some geographical areas where it is paramount to avoid protocol requirements that could impact real-world clinical care and routine clinical practice.

- Addressing real-world outcomes outside of a controlled clinical trial setting requires more flexible data collection. From study design conception, clarity is required in terms of the objectives to permit the selection of the data variables necessary to address...
Table 1. Key Protocol Elements

<table>
<thead>
<tr>
<th>FEATURES</th>
<th>DESCRIPTION</th>
</tr>
</thead>
</table>
| **Rationale** | • Provides a review of available published and unpublished data  
• Identifies a clear evidence gap |
| **Study Objectives** | • Clearly states the study objective(s), using clear and detailed wording to define the study question(s) |
| **Details** | • study design (e.g., cross-sectional, historical, prospective, cohort, case control)  
• methodology (e.g., site-based, survey, direct to patient, electronic medical record extraction, electronic healthcare database)  
• type of study (e.g., chart review, prospective, registry)  
• patient population  
• number of sites  
• expected study duration and duration of tasks  
• study schematic  
• schedule of events/visits  
• Provides results of any preliminary feasibility assessment  
• Provides considerations for patient recruitment and retention  
• Lists criteria for inclusion and exclusion of potential participants  
• Describes any sources of potential bias  
• Describes the data sources (e.g., electronic medical charts, claims databases, surveys)  
• Clearly defines the outcomes of interest, in priority from primary to exploratory  
• Outlines that any treatment(s) received by the patient during the study is independent of, and therefore not impacted by, the study protocol |
| **Design, Selection Criteria, Data Source** | • Summarizes the data collection method and monitoring plan. For site-based studies, includes measures to optimize site engagement. Highlights expected burden/benefits for sites/patients/caregivers, mentions any incentives/compensations  
• Describes methods for handling missing data and the process of building that into the data collection tool  
• Provides an explanation of the procedures ensuring data quality and review |
| **Data Collection, Data Management, Quality Control of Data** | • Describes the statistical analysis sets, subgroup or interim analysis, as well as high level detail of planned statistics  
• Defines the study sample size and precision estimates to achieve the study objective(s) |
| **Ethics, Privacy, and Pharmacovigilance Reporting** | • Describes the study related ethical considerations and planned submission for ethics approval  
• Lists the steps to be taken to protect patient personal data and confidentiality  
• Details how informed consent is to be obtained (where needed)  
• Provides criteria for participant withdrawal or discontinuation, and site or study termination  
• Elaborates the procedures for the collection and reporting of adverse events/adverse drug reactions  
• Clarifies roles and reporting/publication plans |
the study questions and outcomes. A detailed definition of the variables in the protocol will allow identification of any difficulty upfront and facilitate the creation of the case report form, if any.

- **Design and methodological considerations differ depending on the protocol’s intended audience.** For example, if the study aim is to provide additional information on post-marketing safety in Europe, then the protocol should adhere to applicable regulatory regulations such as the European Medicines Agency (EMA) Good Pharmacovigilance Practices (GVP) Module VIII,14 and the EMA Post-Authorisation Safety Studies (PASS),15 or abide by European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).16 These studies may require review and approval from regulatory agencies prior to implementation, and the EMA PASS protocol template or ENCePP protocol checklist17 may need to be consulted during protocol development.

- Adequate time should be taken to coordinate stakeholder input and accurately review the protocol. Discrepancies can lead to amendments or extension of **study timelines.**18

**Key Operational Considerations**

As the protocol provides all parties involved in a study a reference document for consultation to assist with study implementation, it is expected that downstream study challenges will have been proactively accounted for during development.

> The protocol bridges the gap between the research concept and the study conduct.

Clinical trial investigators and sites are not always suitable for non-interventional studies, therefore, it is important to perform outreach concurrent to protocol development to identify the most suitable investigators and sites for study participation, while taking into account marketing authorization, healthcare environment and routine clinical care, geographical features, ethics, data protection, notifications to authorities, and reporting requirements. As data sources exist in various formats and systems in the real world, it is critical to determine the best approach for collecting complete and quality data. Thus, collaboration between the protocol writer and operations allows the integration of relevant study details and realistic assumptions into the protocol during its development.

**Summary**

While there are challenges and considerations to drafting all study protocols, those designed for real-world studies have additional layers of complexity as they need to be developed in such a way as not to alter real-world routine clinical care patterns. The protocol, derived from the sponsor’s strategic needs, must guide and enable the

---

**Recommendations for a Real-World Study Protocol**

- Present clear, detailed, and measurable objectives
- Delineate a strong scientific approach that is operationally feasible
- Include description of the variables chosen to estimate the outcomes of interest
- Include potential covariates or confounding factors
- Adhere to sponsor standards; comply with internal policies and good documentation practices (GDP)
- Allow for the anticipation of issues and upfront agreements to all study objectives and procedures

---

**Figure 4. Lifecycle of Protocol Development and Study Execution Based on Strategic Need**
REFERENCES


For more information, please contact
Marielle.Bassel@evidera.com, Laura.Sayegh@evidera.com, Sofia.Fernandes@ppdi.com or Delphine.Saragoussi@evidera.com.